Viral proteases as therapeutic targets

0565334 - ÚOCHB 2023 RIV NL eng J - Článek v odborném periodiku
Majerová, Taťána - Konvalinka, Jan
Viral proteases as therapeutic targets.
Molecular Aspects of Medicine. Roč. 88, December (2022), č. článku 101159. ISSN 0098-2997. E-ISSN 1872-9452
Grant CEP: GA MŠMT(CZ) LX22NPO5103
Institucionální podpora: RVO:61388963
Klíčová slova: hepatitis C virus * human immunodeficiency virus * orally bioavailable inhibitor
Obor OECD: Virology
Impakt faktor: 10.6, rok: 2022
Způsob publikování: Open access
https://doi.org/10.1016/j.mam.2022.101159

Some medically important viruses―including retroviruses, flaviviruses, coronaviruses, and herpesviruses―code for a protease, which is indispensable for viral maturation and pathogenesis. Viral protease inhibitors have become an important class of antiviral drugs. Development of the first-in-class viral protease inhibitor saquinavir, which targets HIV protease, started a new era in the treatment of chronic viral diseases. Combining several drugs that target different steps of the viral life cycle enables use of lower doses of individual drugs (and thereby reduction of potential side effects, which frequently occur during long term therapy) and reduces drug-resistance development. Currently, several HIV and HCV protease inhibitors are routinely used in clinical practice. In addition, a drug including an inhibitor of SARS-CoV-2 main protease, nirmatrelvir (co-administered with a pharmacokinetic booster ritonavir as Paxlovid®), was recently authorized for emergency use. This review summarizes the basic features of the proteases of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and SARS-CoV-2 and discusses the properties of their inhibitors in clinical use, as well as development of compounds in the pipeline.
Trvalý link: https://hdl.handle.net/11104/0336883